TBK1 and metabolic dysfunction-associated steatotic liver disease: Recent research suggested AM inhibited IκB kinase epsilon (IKKε) and TANK-binding kinase 1 (TBK1), implicated in various diseases including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, obesity, rheumatoid arthritis, and tumor10-13.